The U.S. Court of Appeals for the Federal Circuit rejected an appeal from Dr. Reddy's Laboratories and Teva Pharmaceutical Industries that challenged Eisai's patent for Aciphex, a treatment for stomach ulcer. The decision prohibits the generic-drug firms from making their versions until the patent expires in May 2013.

Full Story:

Related Summaries